Home » Roche’s MabThera Recommended by NICE When TNF Inhibitors Fail
Roche’s MabThera Recommended by NICE When TNF Inhibitors Fail
March 16, 2010
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended Roche’s MabThera plus methotrexate for rheumatoid arthritis
when treatment with at least one tumor necrosis factor (TNF) inhibitor has failed.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor